Allen Andrew R 4

What Happened
Andrew R. Allen, a director of Cullinan Therapeutics, was granted a derivative award on 2026-06-16 representing the right to purchase 21,781 shares of the company's common stock. The Form 4 reports the award as an acquisition at $0.00 (award/grant), indicating a grant of options/rights rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-06-16; Form 4 filed 2026-06-18 (timely filing).
• Reported amount: option to acquire 21,781 shares; acquisition price shown as $0.00 in the filing excerpt.
• Vesting: The option vests in full on the earlier of (i) June 16, 2027 or (ii) the date of the issuer's next annual meeting, subject to Allen's continued service as a director. (Footnote F1)
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction type: Award/derivative grant (not an immediate purchase or sale).

Context
This is a standard director equity award (an option/rights grant) intended to align a director’s interests with shareholders. Because the award vests in the future and was not exercised or sold immediately, it does not reflect a cash purchase or liquidation by the director.